Results 211 to 220 of about 205,233 (331)

Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder. [PDF]

Br J Clin Pharmacol
Whiteside GT, He E, Shet MS, Zhou M, Ahmad M, Harris SC.   +5 more
europepmc   +1 more source

Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign. [PDF]

Int J Mol Sci, 2020
Gomez-Gutierrez P, Perez JJ.
europepmc   +1 more source

Different conformational responses of the β₂-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline. [PDF]

Natl Sci Rev, 2021
Yang F, Ling S, Zhou Y, Zhang Y, Lv P, Liu S, Fang W, Sun W, Hu LA, Zhang L, Shi P, Tian C.   +11 more
europepmc   +1 more source

An Engineered Solidified Peptide Hemocyte Sponge as Nanomotor Storage to Combat Bacterial Colitis

Advanced Science, EarlyView.
Peptides immobilized via nickel coordination can stabilize the framework structure. Following coating with red blood cell membranes, these constructs are capable of continuously sequestering endotoxins and mitigating colonic pathogenic damage by alleviating bacterial‐induced ferroptosis.
Yuxin Fang, Jianming Yan, Tongxin Yu, Zichuan An, Kaikai Lv, Chenyu Xue, Hongyang Yu, Na Dong, Anshan Shan   +8 more
wiley   +1 more source

Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models. [PDF]

Nat Commun
Robert J, Feuillolay M, de Temple-Llavero M, Akossi RF, Mhanna V, Cheraï M, Fourcade G, Charlotte F, Tchitchek N, Mi T, Youngblood B, Vazquez T, Rosenzwajg M, Klatzmann D.   +13 more
europepmc   +1 more source

Time course for blood pressure lowering of beta-blockers with partial agonist activity. [PDF]

Cochrane Database Syst Rev, 2020
Zhang XY, Soufi S, Dormuth C, Musini VM.
europepmc   +1 more source

A highly D₃R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D₃R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. [PDF]

Neuropsychopharmacology, 2022
Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu ES, Friedman J, Lam J, Rais R, Reed JF, Bloom SH, Swanson TL, Schmachtenberg JL, Eshleman AJ, Janowsky A, Xi ZX, Newman AH.   +16 more
europepmc   +1 more source

Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

Advanced Science, EarlyView.
The ultimate goal of cancer theranostics is to get imaging agents and therapeutic cargo to tumor sites when and where they are required. “Smart” systems should be developed. This review discusses the characteristics of physiological stimuli, types and action modes of external stimuli, construction approaches and working principles, as well as ...
Wenting Hu, Binglin Ye, Guocan Yu, Feihe Huang, Zhengwei Mao   +4 more
wiley   +1 more source

Discovery of a novel binding pocket in PPARγ for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis. [PDF]

Front Chem
Wang Z, Shui K, Zhang Z, Chen Y, Yang N, Ji S, Shen P, Tian Q.   +7 more
europepmc   +1 more source

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M₁ -receptor partial agonist for the treatment of dementias. [PDF]

Br J Clin Pharmacol, 2021
Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ.   +14 more
europepmc   +1 more source